Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics

NCT01654120 · Completed

Last updated 2026-05-28

This clinical trial is testing whether adding the medication liraglutide to high-dose insulin helps lower blood sugar levels in adults with type 2 diabetes over a six-month period.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 37 people

Who can join Ages 18–80 · all sexes

Timeline Started 2011-12 · est. completion 2013-11

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01654120 ↗

Description as written by the study sponsor.

The purpose of this study is to determine the effect of adding liraglutide to high dose insulin therapy compared to high dose insulin therapy alone in patients with insulin-treated Type 2 diabetes with insulin requirements of \> 100 units of insulin per day.

Treatments tested

Liraglutide also known as Victoza Drug

SC, 1.8mg,QD, six months to one year
Insulin also known as U-500, Levemir, Novolog Drug

SC, will be titrated during the study, 4 times a day, 1 year

Main thing measured	Change from baseline in HbA1c at six months
Sponsor	Mountain Diabetes and Endocrine Center
Conditions studied	Diabetes Mellitus, Type II
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01654120 ↗